Pierre Fontana

Summary

Affiliation: University of Geneva
Country: Switzerland

Publications

  1. ncbi [Frequently asked questions on clopidogrel treatment: indications, resistance, and biological evaluation in vascular patients]
    Pierre Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, HUG, 1211 Geneve 14
    Rev Med Suisse 4:360-3. 2008
  2. ncbi Assessing aspirin responsiveness using the Verify Now Aspirin assay
    P Fontana
    Division of Angiology and Hemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Thromb Res 121:581-2. 2008
  3. ncbi [Haemostasis. Aspirin and clopidogrel platelet resistances]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, Faculté de médecine et HUG, 1211 Geneve 14
    Rev Med Suisse 2:25-9. 2006
  4. ncbi New antiplatelet strategies in atherothrombosis and their indications
    P Fontana
    Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Eur J Vasc Endovasc Surg 34:10-7. 2007
  5. ncbi [Pharmacogenetics and antiplatelet drugs]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, Faculte de Medecine, Hopital Cantonal Universitaire, 24, Rue Micheli du Crest, 1211 Geneve 14, Suisse
    Rev Med Interne 26:725-32. 2005
  6. ncbi [Update on antithrombotic treatments in arterial diseases]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, Faculté de médecine et HUG, Geneve
    Rev Med Suisse 3:351-2, 354-6. 2007
  7. ncbi Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness
    Pierre Fontana
    Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Thromb Res 121:463-8. 2008
  8. ncbi Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers
    P Fontana
    Department of Internal Medicine, Faculty of Medicine, Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland
    J Thromb Haemost 4:813-9. 2006
  9. ncbi Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management
    Jean Luc Reny
    General Internal Medicine Division, Department of Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland
    Cardiovasc Ther 30:e41-50. 2012
  10. ncbi Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study
    Jean Luc Reny
    Division of General Internal Medicine, University Hospitals of Geneva, 4, rue Gabrielle Perret Gentil, CH 1211 Geneva 14, Switzerland
    Circulation 125:3201-10. 2012

Collaborators

Detail Information

Publications30

  1. ncbi [Frequently asked questions on clopidogrel treatment: indications, resistance, and biological evaluation in vascular patients]
    Pierre Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, HUG, 1211 Geneve 14
    Rev Med Suisse 4:360-3. 2008
    ....
  2. ncbi Assessing aspirin responsiveness using the Verify Now Aspirin assay
    P Fontana
    Division of Angiology and Hemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Thromb Res 121:581-2. 2008
  3. ncbi [Haemostasis. Aspirin and clopidogrel platelet resistances]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, Faculté de médecine et HUG, 1211 Geneve 14
    Rev Med Suisse 2:25-9. 2006
    ..New compounds with a more potent effect are emerging and might be useful in clinically relevant resistances...
  4. ncbi New antiplatelet strategies in atherothrombosis and their indications
    P Fontana
    Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Eur J Vasc Endovasc Surg 34:10-7. 2007
    ..New antiplatelet strategies are in the pipeline, and clinically relevant laboratory tests of APA response may soon help to tailor treatment...
  5. ncbi [Pharmacogenetics and antiplatelet drugs]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, Faculte de Medecine, Hopital Cantonal Universitaire, 24, Rue Micheli du Crest, 1211 Geneve 14, Suisse
    Rev Med Interne 26:725-32. 2005
    ..In the next future, phenotypic or genotypic studies could be available to tailor the prescription of antiplatelet drugs...
  6. ncbi [Update on antithrombotic treatments in arterial diseases]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, Faculté de médecine et HUG, Geneve
    Rev Med Suisse 3:351-2, 354-6. 2007
    ..This review focuses on the indications of the currently available antithrombotic agents in arterial diseases of atherothrombotic origin...
  7. ncbi Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness
    Pierre Fontana
    Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    Thromb Res 121:463-8. 2008
    ..The second aim is to test the influence of the CYP 2C19*2 allele on clopidogrel responsiveness...
  8. ncbi Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers
    P Fontana
    Department of Internal Medicine, Faculty of Medicine, Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland
    J Thromb Haemost 4:813-9. 2006
    ..Some data suggest that biological 'resistance' to aspirin or clopidogrel may influence clinical outcome...
  9. ncbi Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management
    Jean Luc Reny
    General Internal Medicine Division, Department of Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland
    Cardiovasc Ther 30:e41-50. 2012
    ..New and more potent antiplatelet drugs may overcome the clinical consequences of the poor response to antiplatelet agents...
  10. ncbi Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study
    Jean Luc Reny
    Division of General Internal Medicine, University Hospitals of Geneva, 4, rue Gabrielle Perret Gentil, CH 1211 Geneva 14, Switzerland
    Circulation 125:3201-10. 2012
    ....
  11. ncbi Platelet proteomics
    Anne Zufferey
    Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland
    Mass Spectrom Rev 31:331-51. 2012
    ....
  12. ncbi Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients
    Anne Zufferey
    Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Switzerland
    Thromb Haemost 106:466-74. 2011
    ..This index is not dependent on clinical or biological variables, suggesting that genetic factors regulate platelet reactivity in these patients...
  13. ncbi [Evaluating the biological efficacy of clopidogrel: genotype or phenotype?]
    Pierre Fontana
    Service d angiologie et d hémostase, HUG, Geneve
    Rev Med Suisse 6:302-5. 2010
    ..The VASP assay and the 2C19 genotyping are candidates for the identification of patients at risk; this is the focus of the present review...
  14. ncbi Not all statins interfere with clopidogrel during antiplatelet therapy
    F Mach
    University Hospital, Geneva, Switzerland
    Eur J Clin Invest 35:476-81. 2005
    ..The objective of the present study was to define which statin might interfere with the antiaggregation property of clopidogrel...
  15. ncbi [Diagnosis and management of mild bleeding disorders]
    P Fontana
    Service d angiologie et d hémostase, Departement de Medecine Interne, HUG, 1211 Geneve
    Rev Med Suisse 4:122-6. 2008
    ..Several pharmacological agents are available; however, before prophylactic administration of such drugs, a trade-off between their thrombotic risks and excessive bleeding should be made...
  16. ncbi [Monitoring of heparins and of anticoagulants]
    Yan Beauverd
    Service de médecine interne générale, Departement de Medecine Interne, de réhabilitation et gériatrie, HUG, 1211 Geneve 14
    Rev Med Suisse 7:2014-7. 2011
    ..Unfractionated heparin requires close monitoring by aPTT and/or anti-FXa activity while LMWH and fondaparinux do not require biological surveillance except in a few specific situations...
  17. ncbi [Update on new antithrombotic treatments]
    F Boehlen
    Unité D Hémostase Service, d angiologie et d hémostase, Département de médicine interne, HUG, Geneve
    Rev Med Suisse 6:109-12. 2010
    ..Studies have shown an increased bleeding risk for some of them as well as unexpected side effects. In the next future, these new molecules could allow a more individualised prescription of antithrombotic agents...
  18. ncbi Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis
    C Combescure
    Division of Clinical Epidemiology, Geneva University Hospital, Geneva, Switzerland
    J Thromb Haemost 8:923-33. 2010
    ..BSUMMARY BACKGROUND: Previous studies have shown an important risk of cardiovascular events in patients with clopidogrel biological non-response, and data have shown considerable, unexplored heterogeneity...
  19. ncbi [A reference to know: the 2008 Chest Supplement on antithrombotic agents]
    Philippe de Moerloose
    Unite d hémostase, Departement de Medecine Interne, Faculté de médecine de Genève HUG, 1211 Geneve 14
    Rev Med Suisse 5:110-3. 2009
    ..We review some recommendations about the appropriate use of anticoagulants to prevent and treat venous thromboembolic diseases as well as the use of antiplatelet agents in case of arterial diseases...
  20. ncbi Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
    Pierre Fontana
    Service d Hématologie Biologique A, Hôpital Européen Georges Pompidou and Inserm Unité 428, Faculte des Sciences Pharmaceutiques et Biologiques, Universite Paris V, Paris, France
    Circulation 108:989-95. 2003
    ..Some studies have shown interindividual differences in ADP-induced platelet aggregation responses ex vivo, but the mechanisms underlying this variability are unknown...
  21. ncbi An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN
    Annabelle Dupont
    Service d Hématologie Biologique and INSERM Unité 428, Hopital Europeen Georges Pompidou, Faculte des Sciences Pharmaceutiques et Biologiques, Universite Paris V, Paris, France
    Blood 101:1833-40. 2003
    ..The IVSn-14 A/T intronic variation may therefore be clinically relevant...
  22. ncbi Aspirin response variability assessed with the PFA-100 device
    Jean-Luc Reny
    Thromb Haemost 99:968-9; author reply 969. 2008
  23. ncbi Laboratory-defined aspirin resistance and recurrent cardiovascular events
    Pierre Fontana
    Arch Intern Med 168:549-50. 2008
  24. ncbi Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers
    Pierre Fontana
    INSERM Unité 765, Hôpital Européen Georges Pompidou AP HP, Paris, France
    Thromb Haemost 96:356-60. 2006
    ..As C795T and C924T have been linked to clinical disorders in which TxA2 plays a key role, the possible role of the G1686A and T1712C SNP should also be examined in selected diseases...
  25. ncbi Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy
    Simon M G Smith
    Cardiovascular Research Unit, University of Sheffield, Division of Clinical Sciences North, Northern General Hospital, Sheffield, UK
    Platelets 17:250-8. 2006
    ..In conclusion, common sequence variations within the P2Y12 and CYP3A5 genes do not contribute any major effect to the inter-patient variability in clopidogrel efficacy...
  26. ncbi P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study
    Pierre Fontana
    INSERM U 428, Hôpital Européen Georges Pompidou et Université Paris V, Paris, France
    Circulation 108:2971-3. 2003
    ..Because platelets play a key role in atherosclerosis and arterial thrombosis, we tested the possible link between the H2 haplotype and the risk of peripheral arterial disease (PAD) in a case-control study...
  27. ncbi Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia
    Pierre Fontana
    Division of Angiology and Hemostasis, Geneva University Hospital, 24, rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
    Thromb Haemost 91:196-7. 2004
  28. ncbi [Study of primary hemostasis in vitro with the Platelet Function Analyzer (PFA-100)]
    Guido Reber
    Division d Angiologie et Hémostase, Hopitaux Universitaires de Geneve
    Rev Med Suisse Romande 123:491-4. 2003
    ..This device appears an useful complement to aggregometry...
  29. ncbi The thrombomodulin-1208/-1209delTT gene promoter polymorphism does not affect basal or LPS-dependent monocyte TM mRNA transcription in healthy volunteers
    Jean Luc Reny
    Thromb Haemost 94:686-7. 2005
  30. ncbi Physiological plasma Gas6 levels do not influence platelet aggregation
    Sylvain Clauser
    Arterioscler Thromb Vasc Biol 26:e22. 2006